Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

LAUSANNE, Switzerland, Feb 8, 2022 - (ACN Newswire) - Oculis S.A. ("Oculis"), a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the further strengthening of the Company's executive leadership team with the appointment of Dr. Bastian Dehmel as global Chief Development Officer, based in Oculis' corporate headquarters in Lausanne, Switzerland. At Oculis, Dr. Dehmel will be responsible for driving the further development of the Company's strong advanced pipeline of innovative ophthalmology therapies through the New Drug Application stage.

Dr. Dehmel brings close to 20 years of global biotechnology and pharmaceutical industry experience, spanning early and late-phase drug development, clinical operations, biostatistics, and regulatory and medical affairs across multiple therapeutic areas. He joins Oculis from OxThera, a Swedish biopharma company, where he was Chief Medical Officer. Prior to this, he spent more than 10 years at Amgen where he held roles of increasing responsibility, both in the European and Global headquarters, where he led its global Phase III EVOLVE study (Sensipar(R)/Mimpara(R)) and co-led the global product strategy team. He has also held medical advisory roles at Novo Nordisk in Denmark and GlaxoSmithKline in Germany.

Dr. Dehmel received his clinical training in Internal Medicine at Charite University and worked as a post-doc at the Max-Delbruck Center for Molecular Medicine, both in Berlin, Germany.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: "Bastian has a wealth of international experience in leading global clinical development programs gained both from large pharma and innovative biotech companies. We are excited to have him join Oculis as we further accelerate our innovative pipeline of transformational treatments in ophthalmology. His knowledge and expertise will be key in the next phase of our journey to successfully bring to market Oculis' novel product candidates for the benefit of patients globally."

Dr. Bastian Dehmel, Chief Development Officer of Oculis, added: "Oculis's mission to seek innovative solutions to ophthalmology diseases that transform the lives of patients is bold and exciting and I am delighted to join such an inspiring team. Oculis has already built a unique and highly differentiated pipeline and I look forward to further supporting its progress towards commercialization with my experience in executing global drug development programs."

About Oculis
Headquartered in Lausanne, Switzerland with global operations in Europe, the U.S. and China, Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Oculis has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatments, which are non-invasive and represent an unprecedented technical advance for patients with retinal edema and front-of-the-eye diseases. In addition, Oculis' formulation discovery and innovation capabilities enable the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.
To learn more, please visit www.oculis.com


Source: Oculis

Copyright 2022 ACN Newswire . All rights reserved.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.